Zhou Xin, Du Yiping, Huang Zebo, Xu Jun, Qiu Tianzhu, Wang Jian, Wang Tongshan, Zhu Wei, Liu Ping
Department of Oncology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
PLoS One. 2014 Jun 26;9(6):e101119. doi: 10.1371/journal.pone.0101119. eCollection 2014.
Recently, more and more studies investigated the association of inflammation parameters such as the Platelet Lymphocyte Ratio (PLR) and the prognosis of various cancers. However, the prognostic role of PLR in cancer remains controversial.
We conducted a meta-analysis of published studies to evaluate the prognostic value of PLR in various cancers. In order to investigate the association between PLR and overall survival (OS), the hazard ratio (HR) and its 95% confidence interval (CI) were calculated.
A total of 13,964 patients from 26 studies were included in the analysis. The summary results showed that elevated PLR was a negative predictor for OS with HR of 1.60 (95%CI: 1.35-1.90; Pheterogeneity <0.001). Subgroup analysis revealed that increased PLR was a negative prognostic marker in patients with gastric cancer (HR = 1.35, 95%CI: 0.80-2.25, Pheterogeneity = 0.011), colorectal cancer (HR = 1.65, 95%CI: 1.33-2.05, Pheterogeneity = 0.995), hepatocellular carcinoma (HR = 3.07, 95% CI: 2.04-4.62, Pheterogeneity = 0.133), ovarian cancer (HR = 1.57, 95%CI: 1.07-2.31, Pheterogeneity = 0.641) and non-small cell lung cancer (NSCLC) (HR = 1.85, 95% CI: 1.42-2.41, Pheterogeneity = 0.451) except for pancreatic cancer (HR = 1.00, 95%CI: 0.92-1.09, Pheterogeneity = 0.388).
The meta-analysis demonstrated that PLR could act as a significant biomarker in the prognosis of various cancers.
最近，越来越多的研究调查了诸如血小板淋巴细胞比率（PLR）等炎症参数与各种癌症预后之间的关联。然而，PLR在癌症中的预后作用仍存在争议。
我们对已发表的研究进行了荟萃分析，以评估PLR在各种癌症中的预后价值。为了研究PLR与总生存期（OS）之间的关联，计算了风险比（HR）及其95%置信区间（CI）。
分析共纳入了来自26项研究的13964例患者。汇总结果显示，PLR升高是OS的负性预测指标，HR为1.60（95%CI：1.35 - 1.90；异质性P<0.001）。亚组分析显示，除胰腺癌（HR = 1.00，95%CI：0.92 - 1.09，异质性P = 0.388）外，PLR升高在胃癌（HR = 1.35，95%CI：0.80 - 2.25，异质性P = 0.011）、结直肠癌（HR = 1.65，95%CI：1.33 - 2.05，异质性P = 0.995）、肝细胞癌（HR = 3.07，95%CI：2.04 - 4.62，异质性P = 0.133）、卵巢癌（HR = 1.57，95%CI：1.07 - 2.31，异质性P = 0.641）和非小细胞肺癌（NSCLC）（HR = 1.85，95%CI：1.42 - 2.41，异质性P = 0.451）中是负性预后标志物。
荟萃分析表明，PLR可作为各种癌症预后的重要生物标志物。
